首页> 美国卫生研究院文献>Current Therapeutic Research Clinical and Experimental >Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment
【2h】

Comparison of five-day Helicobacter pylori eradication regimens: rabeprazole-based and omeprazole-based regimens with and without omeprazole pretreatment

机译:五天幽门螺杆菌根除方案的比较:雷贝拉唑和奥美拉唑为基础的方案有或没有奥美拉唑预处理

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: The onset of antisecretory activity of rabeprazole is faster than that of omeprazole.>Objective: This study was performed to compare the efficacy of short-term rabeprazole-based triple therapy with that of omeprazole-based triple therapy and to determine the influence of omeprazole pretreatment in omeprazole-based short-term triple therapy.>Methods: This was a 2-center, open-label, prospective, randomized study. Patients who tested positive for Helicobacter (formerly Campylobacter) pylori were randomized to one of three 5-day regimens: (1) rabeprazole 20 mg BID, amoxicillin 500 mg TID, and clarithromycin 400 mg BID (RAC group); (2) omeprazole 20 mg BID, amoxicillin 500 mg TID, and clarithromycin 400 mg BID without omeprazole pretreatment (OAC1 group); and (3) omeprazole 20 mg BID, amoxicillin 500 mg TID, and clarithromycin 400 mg BID with 5 days of omeprazole pretreatment 20 mg BID (OAC2 group). Eradication was assessed by 13C-urea breath test and rapid urease test ∼1 month after completion of treatment. All patients who entered this study were included in the intent-to-treat (ITT) analysis, patients who completed the study were included in the per-protocol (PP) analysis, and patients who did not undergo the 13C-urea breath test and rapid urease test were included in the all-patients-treated (APT) analysis.>Results: A total of 120 patients (86 men, 34 women; mean [SD] age, 55.8 [14.3] years; range, 19–86 years) were assigned to the RAC, OAC1, or OAC2 group (40 patients in each group). ITT, PP, and APT eradication rates in the RAC group were 90%, 92%, and 90%, respectively; in the OAC1 group, 75%, 83%, and 75%; and in the OAC2 group, 85%, 90%, and 87%. These eradication rates were not significantly different between groups.>Conclusions: Eradication rates did not differ significantly between the three 5-day proton pump inhibitor–based triple therapies in this study population. However, 5-day rabeprazole-based triple therapy tends to be more effective than 5-day omeprazole-based triple therapy in the eradication of H pylori, and treatment with omeprazole before eradication therapy may improve the eradication rates of 5-day omeprazole-based therapy.
机译:>背景:雷贝拉唑的抗分泌活性起效快于奥美拉唑。>目的:该研究旨在比较基于雷贝拉唑的短期三联疗法与奥美拉唑的疗效。 >方法:这是一项以2个中心,开放标签,前瞻性,随机对照的研究。该研究旨在确定基于奥美拉唑的三联疗法的疗效,并确定奥美拉唑预处理对基于奥美拉唑的短期三联疗法的影响。幽门螺杆菌(以前为弯曲杆菌)检测阳性的患者被随机分配到以下三种5天治疗方案之一:(1)雷贝拉唑20 mg BID,阿莫西林500 mg TID,克拉霉素400 mg BID(RAC组); (2)未经奥美拉唑预处理的奥美拉唑BID 20 mg,阿莫西林500 mg TID和克拉霉素400 mg BID(OAC1组); (3)奥美拉唑预处理20 mg BID 5天,奥美拉唑20 mg BID,阿莫西林500 mg TID,克拉霉素400 mg BID(OAC2组)。治疗结束后约1个月通过 13 尿素呼气试验和快速尿素酶试验评估根除情况。所有参加本研究的患者都包括在意向治疗(ITT)分析中,完成研究的患者也包括在按方案(PP)分析中,而未接受 13 C-尿素呼气试验和快速尿素酶试验已纳入所有患者治疗(APT)分析中。>结果:共有120例患者(男性86例,女性34例,平均[SD])年龄为55.8 [14.3]岁;范围为19-86岁)被分配给RAC,OAC1或OAC2组(每组40例)。 RAC组的ITT,PP和APT根除率分别为90%,92%和90%。在OAC1组中,分别为75%,83%和75%;在OAC2组中,分别为85%,90%和87%。各组之间的根除率没有显着差异。>结论:在该研究人群中,基于3个5天的质子泵抑制剂的三联疗法在根除率上没有显着差异。然而,在根除幽门螺杆菌中,基于雷贝拉唑的5天三联疗法往往比基于奥美拉唑的5天三联疗法更有效,并且根除治疗前用奥美拉唑治疗可能会提高基于奥美拉唑的5天根除率。治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号